Our proprietary QuAD³ platform allows us to define novel biological insights from our deep phenotypic and genomic patient cohorts. Comparing primary tumor with metastatic drivers across the cohorts allows us to identify mechanisms driving disease progression from the primary tumor to cancer relapse and metastasis. These insights provide a deep understanding of resistance mechanisms, enabling patient enrichment and the clinical development of our innovative therapeutic programs.
We used this causal inference approach in our recent publication, “Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.”
Our QuAD³ Platform allows for the analysis of multiple data types to yield novel phenotypic and clinical-genomic insights.
We leverage multiple algorithms to classify novel patterns and biological pathways linked to causal dependency.
Use biomarker phenotype insights to identify favorable phenotypes sensitive to treatment.